REGN vs BAM Comparison

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Brookfield Asset Management Ltd is an alternative asset manager with over $1 trillion of Assets Under Management across infrastructure, renewable power and transition, private equity, real estate, and credit. It offers a range of alternative investment products to over 2,400 institutional clients around the world-including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies and private wealth investors which also continues to grow with approximately 60,000 clients representing over 8% of capital raised. The company provide a diversified suite of alternative investment strategies to its clients and are constantly seeking to innovate new strategies to meet their needs.